Skip to main content
Midas Edge

Century Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 19, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 19, 2025

IPSC$1.81+7.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets

**(**In thousands, except share and per share amounts)

​​​​​​​
​ · ​ · ​ · ​ · ​
​​December 31, 2024December 31, 2023
Assets​​​​​​
​​​​​​​
Current assets​​​​​​
Cash and cash equivalents​$58,441​$47,324
Short-term investments​130,851​125,414
Prepaid expenses and other current assets​4,759​4,256
Total current assets​194,051​176,994
​​​​​​​
Property and equipment, net​62,141​71,705
Operating lease right-of-use assets​​28,706​​20,376
Restricted cash​​2,772​​1,979
Long-term investments​30,818​89,096
Intangible assets​​34,200​​—
Security deposits and non-current assets​528​541
Total assets​$353,216​$360,691
​​​​​​​
Liabilities and stockholders’ equity​​
​​​​​​​
Current liabilities​​
Accounts payable​$3,075​$2,741
Accrued expenses and other liabilities​17,461​10,149
Deposit liability​​82​​584
Deferred revenue, current​​109,164​​4,372
Total current liabilities​129,782​17,846
​​​​​​​
Operating lease liability, long term​48,960​46,658
Deposit liability, non-current​​-​​56
Deferred revenue, non-current​​-​​111,381
Contingent consideration liability​8,738​—
Deferred tax liability​​4,374​​—
​​​​​​​
Total liabilities​191,854​175,941
​​​​​​​
Commitments and contingencies (Note 10)​​
Stockholders' equity:​​​​​​
Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively​​—​​—
Common stock, $0.0001 par value, 300,000,000 shares authorized; 85,836,429 and 60,335,701 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively​​9​​6
Additional paid-in capital​943,366​840,407
Accumulated deficit​​(782,337)​​(655,771)
Accumulated other comprehensive Income​​324​​108
Total stockholders’ equity​​161,362​​184,750
Total liabilities and stockholders’ equity​$353,216​$360,691
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.